FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2848698840> ?p ?o ?g. }

• W2848698840 endingPage "530" @default.
• W2848698840 startingPage "523" @default.
• W2848698840 abstract "Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD versus PAD without diagnosed CAD, and whether ticagrelor was superior to clopidogrel in reducing that risk. The EUCLID trial randomized 13,885 patients with PAD to antithrombotic monotherapy with ticagrelor or clopidogrel. CAD was defined as prior myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery. Median follow-up was 30 months. Among 4032 (29%) patients with PAD and CAD, 63% had prior MI, 54% prior PCI, and 38% prior CABG. After adjustment for baseline characteristics, patients with PAD and CAD had significantly higher rates of the primary endpoint (cardiovascular death/MI/stroke, 15.3% vs 8.9%, hazard ratio (HR) 1.50, 95% CI: 1.13-1.99; p=0.005), but no statistically significant increase in acute limb ischemia (HR 1.28, 95% CI: 0.57-2.85; p=0.55) or major bleeding (HR 1.10, 95% CI: 0.49-2.48; p=0.81) versus PAD without CAD. Among patients with PAD and CAD, there was no differential treatment effect between ticagrelor versus clopidogrel for the primary efficacy endpoint (HR 1.02, 95% CI: 0.87-1.19; p=0.84), acute limb ischemia (HR 1.03, 95% CI: 0.63-1.69; p=0.89), or major bleeding (HR 1.06, 95% CI: 0.66-1.69; p=0.81). There was a statistically significant interaction between prior coronary stent placement and study treatment ( p=0.03) with a numerical reduction in the primary efficacy endpoint with ticagrelor versus clopidogrel (13.8% vs 16.8%, HR 0.82, 95% CI: 0.65-1.03; p=0.09). Patients with PAD and prior CAD had higher composite rates of cardiovascular death, MI, and ischemic stroke versus PAD without diagnosed CAD. There were no significant differences between ticagrelor and clopidogrel in cardiovascular events or major bleeding. ClinicalTrials.gov Identifier: NCT01732822." @default.
• W2848698840 created "2018-07-19" @default.
• W2848698840 creator A5006133112 @default.
• W2848698840 creator A5014777482 @default.
• W2848698840 creator A5015327081 @default.
• W2848698840 creator A5020758622 @default.
• W2848698840 creator A5033936422 @default.
• W2848698840 creator A5038722538 @default.
• W2848698840 creator A5039432822 @default.
• W2848698840 creator A5044393078 @default.
• W2848698840 creator A5047742264 @default.
• W2848698840 creator A5049378858 @default.
• W2848698840 creator A5053327237 @default.
• W2848698840 creator A5067237537 @default.
• W2848698840 creator A5076746946 @default.
• W2848698840 creator A5076791099 @default.
• W2848698840 creator A5082012532 @default.
• W2848698840 creator A5084489827 @default.
• W2848698840 creator A5088017620 @default.
• W2848698840 date "2018-07-11" @default.
• W2848698840 modified "2023-09-27" @default.
• W2848698840 title "Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial" @default.
• W2848698840 cites W1908289777 @default.
• W2848698840 cites W2011983013 @default.
• W2848698840 cites W2021473250 @default.
• W2848698840 cites W2037500444 @default.
• W2848698840 cites W2037925228 @default.
• W2848698840 cites W2040816046 @default.
• W2848698840 cites W2098413228 @default.
• W2848698840 cites W2119984740 @default.
• W2848698840 cites W2140501627 @default.
• W2848698840 cites W2148374679 @default.
• W2848698840 cites W2163050713 @default.
• W2848698840 cites W2280156152 @default.
• W2848698840 cites W2430015321 @default.
• W2848698840 cites W2556414715 @default.
• W2848698840 cites W2556919357 @default.
• W2848698840 cites W2611241853 @default.
• W2848698840 cites W2611576467 @default.
• W2848698840 cites W311320695 @default.
• W2848698840 doi "https://doi.org/10.1177/1358863x18775594" @default.
• W2848698840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29992857" @default.
• W2848698840 hasPublicationYear "2018" @default.
• W2848698840 type Work @default.
• W2848698840 sameAs 2848698840 @default.
• W2848698840 citedByCount "25" @default.
• W2848698840 countsByYear W28486988402018 @default.
• W2848698840 countsByYear W28486988402019 @default.
• W2848698840 countsByYear W28486988402020 @default.
• W2848698840 countsByYear W28486988402021 @default.
• W2848698840 countsByYear W28486988402022 @default.
• W2848698840 countsByYear W28486988402023 @default.
• W2848698840 crossrefType "journal-article" @default.
• W2848698840 hasAuthorship W2848698840A5006133112 @default.
• W2848698840 hasAuthorship W2848698840A5014777482 @default.
• W2848698840 hasAuthorship W2848698840A5015327081 @default.
• W2848698840 hasAuthorship W2848698840A5020758622 @default.
• W2848698840 hasAuthorship W2848698840A5033936422 @default.
• W2848698840 hasAuthorship W2848698840A5038722538 @default.
• W2848698840 hasAuthorship W2848698840A5039432822 @default.
• W2848698840 hasAuthorship W2848698840A5044393078 @default.
• W2848698840 hasAuthorship W2848698840A5047742264 @default.
• W2848698840 hasAuthorship W2848698840A5049378858 @default.
• W2848698840 hasAuthorship W2848698840A5053327237 @default.
• W2848698840 hasAuthorship W2848698840A5067237537 @default.
• W2848698840 hasAuthorship W2848698840A5076746946 @default.
• W2848698840 hasAuthorship W2848698840A5076791099 @default.
• W2848698840 hasAuthorship W2848698840A5082012532 @default.
• W2848698840 hasAuthorship W2848698840A5084489827 @default.
• W2848698840 hasAuthorship W2848698840A5088017620 @default.
• W2848698840 hasBestOaLocation W28486988401 @default.
• W2848698840 hasConcept C126322002 @default.
• W2848698840 hasConcept C127413603 @default.
• W2848698840 hasConcept C164705383 @default.
• W2848698840 hasConcept C168563851 @default.
• W2848698840 hasConcept C203092338 @default.
• W2848698840 hasConcept C207103383 @default.
• W2848698840 hasConcept C2777849778 @default.
• W2848698840 hasConcept C2778213512 @default.
• W2848698840 hasConcept C2780400711 @default.
• W2848698840 hasConcept C2780645631 @default.
• W2848698840 hasConcept C2780890252 @default.
• W2848698840 hasConcept C44249647 @default.
• W2848698840 hasConcept C45393284 @default.
• W2848698840 hasConcept C500558357 @default.
• W2848698840 hasConcept C71924100 @default.
• W2848698840 hasConcept C78519656 @default.
• W2848698840 hasConceptScore W2848698840C126322002 @default.
• W2848698840 hasConceptScore W2848698840C127413603 @default.
• W2848698840 hasConceptScore W2848698840C164705383 @default.
• W2848698840 hasConceptScore W2848698840C168563851 @default.
• W2848698840 hasConceptScore W2848698840C203092338 @default.
• W2848698840 hasConceptScore W2848698840C207103383 @default.
• W2848698840 hasConceptScore W2848698840C2777849778 @default.
• W2848698840 hasConceptScore W2848698840C2778213512 @default.
• W2848698840 hasConceptScore W2848698840C2780400711 @default.
• W2848698840 hasConceptScore W2848698840C2780645631 @default.
• W2848698840 hasConceptScore W2848698840C2780890252 @default.

• next